ornithylaspartate has been researched along with Hyperammonemia in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (38.46) | 29.6817 |
2010's | 7 (53.85) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Fan, Y; Jiang, H; Li, M; Shao, J; Zhang, M | 1 |
Butterworth, RF | 2 |
Bogomolov, PO; Buyeverov, AO; Matsievich, MV; Mayev, IV; Uvarova, OV | 1 |
Ahn, JO; Chung, JY; Han, SM; Hwang, CY; Lee, YH; Li, Q; Youn, HY | 1 |
Achermann, P; Amodio, P; Angeli, P; Garrido, M; Montagnese, S; Raduazzo, D; Skorucak, J; Spinelli, G; Turco, M | 1 |
Ahmad, I; Alam, A; Butt, AK; Dilshad, A; Khan, AA; Malik, K; Sarwar, S; Shafqat, F | 1 |
Jalan, R; Lee, WM | 1 |
Acharya, SK; Bhatia, V; Khanal, S; Panda, SK; Sreenivas, V | 1 |
Jalan, R; Noiret, L; Olde Damink, SW; Wright, G | 1 |
Blanco Vela, CI; Poo Ramírez, JL | 1 |
Bautista, JD; Grande, L; Ramos Guerrero, RM; Romero Gómez, M; Sánchez Muñoz, D | 1 |
3 review(s) available for ornithylaspartate and Hyperammonemia
Article | Year |
---|---|
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Topics: Ammonia; Dipeptides; End Stage Liver Disease; Humans; Hyperammonemia; Liver; Sarcopenia; Treatment Outcome | 2019 |
Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
Topics: Adipose Tissue; Amino Acids; Ammonia; Arginine; Brain; Dipeptides; Glutamate-Ammonia Ligase; Glutaminase; Hepatic Encephalopathy; Humans; Hyperammonemia; Intestinal Mucosa; Kidney; Liver; Liver Failure; Lung; Muscles; Phenylbutyrates; Sodium Benzoate | 2011 |
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Topics: Ammonia; Brain; Brain Edema; Dipeptides; Flumazenil; Glutaminase; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Inflammation; Intestine, Small; Kidney; Memantine; Models, Molecular; Nerve Tissue Proteins; Nitric Oxide | 2004 |
2 trial(s) available for ornithylaspartate and Hyperammonemia
Article | Year |
---|---|
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognition; Dipeptides; Female; Health Status Indicators; Hepatic Encephalopathy; Humans; Hyperammonemia; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Postprandial Period | 2008 |
Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hyperammonemia; Kaplan-Meier Estimate; Liver Failure, Acute; Male; Probability; Prospective Studies; Reference Values; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
8 other study(ies) available for ornithylaspartate and Hyperammonemia
Article | Year |
---|---|
Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate.
Topics: Ammonia; Animals; Catfishes; Dipeptides; Hyperammonemia; Sodium Chloride | 2022 |
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Topics: Astrocytes; Dipeptides; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Translational Research, Biomedical | 2019 |
Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Topics: Adult; Ammonia; Case-Control Studies; Dipeptides; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Hyperammonemia; Male; Treatment Outcome | 2019 |
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
Topics: Ammonia; Animals; Dipeptides; Dog Diseases; Dogs; Female; Hepatic Encephalopathy; Hyperammonemia; Male | 2016 |
Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Topics: Adult; Brain; Caffeine; Dipeptides; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Wakefulness | 2016 |
Treatment of hyperammonemia in liver failure: a tale of two enzymes.
Topics: Dipeptides; Double-Blind Method; Female; Humans; Hyperammonemia; Liver Failure, Acute; Male; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Treatment Outcome | 2009 |
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Dipeptides; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Quality of Life; Severity of Illness Index; Treatment Outcome; Urea | 2011 |
[In liver cirrhosis, not every "ammonia lowering drug" improves neuropsychiatric deficit].
Topics: Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Hyperammonemia; Neuropsychological Tests; Treatment Outcome | 2001 |